Debevoise & Plimpton is advising Japan’s Sawai Pharmaceutical Co. Ltd. on a $1.05 billion acquisition of Minnesota-based pharmaceutical company Upsher-Smith Laboratories Inc.
Osaka-based Sawai makes generic drugs and plans to expand into the U.S. market by leveraging Upsher-Smith’s distribution network, client relationships and brand reputation. Headquartered in Maple Grove, Minnesota, Upsher-Smith is privately owned by the family of chief executive Mark Evenstad. The company makes about 30 types of drugs, including both generic and patented products.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
